This Program supports implementation of innovative biological, biophysical or cell-based assays for novel biological targets or processes relevant to mental disorders. The program also supports science relevant to several related Common Fund programs: 1) the adaptation and development of scalable assay technologies to explore the underlying biology of novel or poorly characterized members of the Druggable Genome such as G-protein coupled receptors, ion channels, nuclear receptors, and protein kinases (Illuminating the Druggable Genome ); 2) gene function studies in collaboration with the NIH Undiagnosed Diseases Network (UDN) to investigate the underlying genetics, biochemistry and pathophysiology of newly diagnosed diseases identified through the UDN; and, 3) adoption and validation of novel powerful Single Cell Analysis (SCA) approaches by supporting new collaborations of currently funded R01 investigators with developers of the SCA approaches.
It is recommended that applicants review the NIH/NIMH Therapeutics Discovery Research webpage for relevant announcements and guidance.
Applicants are strongly encouraged to discuss their proposals with the Institute contact listed below prior to the submission of their application to ascertain that their proposed work is aligned with NIMH funding priorities.
Yong Yao, Ph.D.
6001 Executive Boulevard, Room 7182B, MSC 9641